Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and efficacy of a Tyrosine Kinase Inhibitor (TKI)
called Nilotinib BE (bioequivalent) in individuals with Early Alzheimer's disease (EAD). This
is a multi-center double blinded, Phase 3 study, that will enroll patients for three years in
approximately 50 centers nationwide. The total duration of the study will be for five years.
Phase:
Phase 3
Details
Lead Sponsor:
KeifeRx, LLC
Collaborators:
Life Molecular Imaging GmbH Sun Pharmaceuticals Industries Limited Worldwide Clinical Trials